Compare · BLCO vs COO
BLCO vs COO
Side-by-side comparison of Bausch + Lomb Corporation (BLCO) and The Cooper Companies Inc. (COO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLCO and COO operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- COO is the larger of the two at $19.03B, about 3.2x BLCO ($5.95B).
- Both names hit the wire about 6 times in the past 4 weeks.
- COO has more recent analyst coverage (25 ratings vs 21 for BLCO).
- Company
- Bausch + Lomb Corporation
- The Cooper Companies Inc.
- Price
- $16.48-1.32%
- $57.91+0.88%
- Market cap
- $5.95B
- $19.03B
- 1M return
- -
- +7.66%
- 1Y return
- -
- -19.55%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- News (4w)
- 6
- 6
- Recent ratings
- 21
- 25
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
The Cooper Companies Inc.
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
Latest BLCO
- SEC Form 8-K filed by Bausch + Lomb Corporation
- Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
- Barclays initiated coverage on Bausch + Lomb with a new price target
- Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
- Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
- SEC Form 144 filed by Bausch + Lomb Corporation
- Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
- Leerink Partners initiated coverage on Bausch + Lomb with a new price target
- Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
- Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
Latest COO
- Barclays initiated coverage on Cooper with a new price target
- New CooperVision® Consumer Insights Report Reveals Multifocal Contact Lenses Are Viewed as a Leading Anti-Aging Solution
- Seneca Polytechnic and CooperVision Canada open Contact Lens Centre of Excellence to help advance the future of vision care
- COOPER COMPANIES, INC. COO INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 14.7% Share Drop
- CooperCompanies Unveils Accelerated CooperVision Innovation Strategy at The Vision Centre Opening
- CooperVision Powers the Next Era of Eye Care with New Global Vision Centre and Major Pipeline Advancements
- JANA Partners Sends Letter to Cooper Board of Directors
- Director Kurzius Lawrence Erik bought $549,320 worth of shares (10,000 units at $54.93), increasing direct ownership by 47% to 31,099 units (SEC Form 4)
- Director Rosebrough Walter M Jr bought $541,640 worth of shares (10,000 units at $54.16) (SEC Form 4)
- Director Kurzius Lawrence Erik bought $539,150 worth of shares (10,000 units at $53.91), increasing direct ownership by 90% to 21,099 units (SEC Form 4)